Peptime Survey 2026: Vendor-Run User Data
In May 2026, peptide vendor Peptime published results from a self-selected online survey of 1,000+ respondents. The post offers a directional read on its engaged audience, not an independent market study. Below: the findings visible in the cited source, with the source relationship and limitations stated explicitly.
Update History ▾
May 19, 2026: Initial publication.
Peptime's 2026 survey is a vendor-run, self-selected audience survey, not a clinical study or an independent market estimate. The cited post reports that 70% of respondents sourced from “Research Use Only” suppliers, while spending was concentrated: the median band was 100–249 US dollars a month and roughly 11% reported 1,000 or more. These figures describe respondents to Peptime's survey only. They are self-reported, unweighted, and not peer-reviewed.
- 70% source from “Research Use Only” suppliers; only 11% go through a local doctor or telehealth provider.
- 68% describe their own use as a “legal gray area”; another 14% call it “probably illegal.”
- Median monthly spend is 100–249 in US dollars; 11% report 1,000 or more per month (roughly 12,000+ a year).
- Tech is the largest single industry cohort — 75% reported use rate, well ahead of finance (46%) and consulting (45%).
- Stacks beat singles on self-rated effectiveness — 3.2/4 for 3+ peptide stacks vs 2.0/4 for single-peptide use.
- The 25–34 subgroup reported a higher use rate — 75% versus 22% in the 18–24 subgroup, without published subgroup counts or weighting.
- 68% rate their experience as “very effective” or “life-changing” — self-report only, no control, heavy selection bias.
About the Survey
In May 2026, Peptime (@ItsPeptime) — a peptide vendor — published headline results from an opt-in survey of 1,000+ respondents. That commercial relationship is material: the survey describes a vendor's self-selected audience and should not be presented as independent market research.
This is not a clinical study. It is a self-selected online survey of people who already had enough interest in peptides to encounter Peptime's survey and finish the questionnaire. That has predictable consequences for the data:
- Selection bias is heavy. Respondents skew toward engaged, current users.
- All outcomes are self-reported. There are no verified labs, biomarkers, or controls.
- Heavy users are likely over-represented. The casual or one-time user is under-counted.
Read with those caveats in mind, the survey is best treated as a market-state snapshot of the engaged peptide user base in 2026 — not as evidence about whether or how well any specific compound works in a general population.
Finding 1: Grey Market Peptides Dominate — 70% of Users Source From RUO Suppliers
The clearest result in the dataset is also the most consequential. Seven in ten respondents reported buying grey market peptides — product sold under a “Research Use Only” label rather than through a prescription pathway. Only about one in five users went through any kind of doctor. The gray market is not a transition state in this data; it is the primary distribution channel.
| Source channel | Share of respondents | What it means |
|---|---|---|
| “Research Use Only” supplier | 70% | Material sold for in-vitro research, not for human use |
| Overseas clinic | 12% | Prescription written abroad, product imported |
| Local doctor or telehealth | 11% | Domestic prescription pathway |
| Friends or informal channels | 9% | Unverified provenance and storage chain |
Awareness of the legal posture is high. 68% of respondents called their own use a “legal gray area,” another 14% described it as “probably illegal,” and only 18% believed what they were doing was clearly legal. The framing matters: the gray market is not a transient state on the way to regulation in this sample. It is the dominant distribution channel and users are explicit that they understand what that means. For anyone reading a research-grade claim, the consequence is that source verification — third-party HPLC, batch COAs, documented cold-chain handling, and a real address — carries more weight than nominal compliance language. Our COA library exists for exactly this reason.
Finding 2: Annual Spend Reaches Five Figures
Spending is concentrated. All figures in this section are self-reported monthly spend in US dollars. The median respondent reported 100–249 a month — consistent with a single GLP-1 product cycled monthly — but the top of the distribution is steep. Roughly 11% reported 1,000 or more a month, which annualises to 12,000 or more per respondent. That puts the heavy-user cohort in territory normally reserved for private school tuition or a car payment.
| Monthly spend tier (USD) | Share of respondents | Approx. annualised (USD) |
|---|---|---|
| Under 100 | (remainder of sample) | < 1,200 |
| 100 – 249 (median band) | Largest single tier | 1,200 – 3,000 |
| 500 – 999 | 18% | 6,000 – 12,000 |
| 1,000 or more | 11% | 12,000 or more |
For market context in the GLP-1 class — the largest contributor to monthly spend — see our GLP-1 medications UAE availability and cost breakdown. The takeaway from the survey is structural: this is not a casual hobbyist category. A meaningful slice of respondents report spending mid-five figures a year, which raises the stakes on cold-chain integrity and batch documentation across the whole category.
Finding 3: Tech Leads Industry Adoption
The industry breakdown reads like a chart of who has both disposable income and an information-dense relationship with their own bodies. Tech sits at the top by a clear margin; healthcare and biotech follow, which suggests a domain-knowledge effect; construction lands surprisingly high, which is harder to explain from the public data alone.
| Industry | Reported use rate | Read |
|---|---|---|
| Technology | 75% | Highest single cohort; high income, high biohacking saturation |
| Healthcare / biotech | 59% | Domain familiarity lowers the activation barrier |
| Construction | 55% | Physical-recovery use case is plausible but unverified |
| Finance | 46% | Disposable income, less category fluency |
| Consulting | 45% | Similar profile to finance |
The number to be careful with here is the construction figure. The survey reaches users through Peptime's vendor audience, which means the industry mix is shaped by who already follows that account — not by the broader workforce. A 55% use rate in a self-selected subset of construction-industry respondents is not the same as a 55% use rate among construction workers generally.
Finding 4: Stacks Beat Singles on Self-Rated Effectiveness
Respondents using a single peptide rated their experience at 2.0/4 (“somewhat effective”). Respondents stacking three or more compounds rated theirs at 3.2/4 (“life-changing”). That is a 60% difference on a self-rating scale, but the survey design cannot establish why the groups differed.
Plausible explanations include different goals, different baseline characteristics, heavier engagement, greater financial commitment, or differences in how respondents interpreted the rating scale. The post does not provide the group-level detail needed to distinguish among them.
The result is descriptive, not causal. The post does not establish that stacking caused the higher rating, that the compounds were correctly identified, or that the compared groups were otherwise similar.
Finding 5: The 25–34 Cohort Reported Higher Use
The use-rate jump between the youngest and the second-youngest cohort is the largest gap reported in the post. Because the sample is self-selected and subgroup sizes are not provided, it should not be generalised to either age group.
| Age cohort | Reported use rate | Read |
|---|---|---|
| 18 – 24 | 22% | Self-selected subgroup; size not reported |
| 25 – 34 | 75% | Largest single jump in the dataset |
The post does not provide a sampling frame, subgroup counts, confidence intervals, or weighting. The comparison is therefore descriptive of respondents, not an age-based population estimate.
Finding 6: 68% Rate Their Experience as “Very Effective” or Better
Self-rated outcomes are the most caveat-heavy number in the survey, and we are surfacing the caveat first: these respondents took a peptide quiz on a peptide information site. They are not a representative sample of anyone, and the rating reflects how engaged users feel about their use, not what any peptide actually does in a controlled setting.
| Self-rating | Share of respondents |
|---|---|
| Life-changing | 26% |
| Very effective | 42% |
| Somewhat effective | 23% |
| Not very effective | 9% |
Roughly 68% sit at “very effective” or above. That number records how respondents answered; it is not evidence that peptides produce those outcomes in a general population, in any specific protocol, or for any specific indication. This self-rating should carry less evidentiary weight than controlled outcome data.
What the Data Tells Us About the 2026 Peptide Market
Three structural reads come out of the dataset, regardless of where the noise sits.
The sourcing result describes this vendor audience, not total demand. The 70% figure is a reported share among Peptime survey respondents. It cannot establish market share without a defined sampling frame. For an evidence-focused explanation of batch documentation, see how to verify a Janoshik COA.
The stacking comparison is hypothesis-generating. The 3+ peptide group reported 3.2/4 versus 2.0/4 for the single-peptide group. Without randomisation, group sizes, or adjustment for baseline differences, the result cannot show that stacking caused the rating difference.
Source provenance changes how the findings should be read. A vendor-run opt-in survey can identify questions worth studying, but it cannot support independent market-share, demographic, or effectiveness claims on its own.
Limitations of a Self-Selected Online Survey
Every number in this article should be read against the same set of constraints. We are surfacing them in one place rather than burying them in footnotes.
- Self-selected sample. Respondents encountered Peptime's survey, opted in, and finished it. They are not a representative slice of any defined population.
- Self-reported responses. No lab verification, no biomarker corroboration, no third-party check on what was actually used or for how long.
- No control group. Comparison to non-users or to placebo is not possible from the data.
- Vendor-run source. Peptime sells peptides, creating a commercial relationship that may shape audience composition, question framing, and response behaviour.
- Recall and framing effects. Monthly spend, stacking effectiveness, and reasons-for-use all depend on how respondents remember and frame their own behaviour.
None of these dismiss the data. They define what it is for. The survey is a directional read on engaged-user behaviour, not a clinical or market-share study. We treat it accordingly.
A Note on Research Use Only
The compounds documented here are for in-vitro laboratory research only. They are not intended for human or veterinary use, diagnosis, treatment, prevention, or cure of any condition. The survey data summarised here describes how respondents reported behaving and feeling; it is not guidance to act on. See our research standards for how we document and verify what we publish.
Our Research Standards
This article summarises a vendor-run community survey and adds source limitations and editorial context. The primary source is Peptime's May 2026 post. Claims not visible in that cited post have been removed; the remaining figures are presented as self-reported survey results, not independently validated measurements. Read our editorial policy →
- Peptime. (2026, May). Insights from 1,000+ peptide users: Survey results [X post]. x.com/ItsPeptime/status/2056380319331438992 — primary source; vendor-run survey.
- FormBlends. (2026). 2026 State of Peptides Report. finance.yahoo.com — broader market context.
- Medscape. (2026). Gray Market Peptides: So Much Hype, So Little Data. medscape.com — clinical perspective on gray-market sourcing.
- New York Post. (2026, January 14). Inside the Peptide Gray Market. nypost.com — consumer-press read on the same phenomenon.
Methodology disclaimer: This article summarises publicly shared findings from a vendor-run, self-reported online survey. Numbers reflect selection bias, self-report effects, a commercial host, and a single audience. They are not peer-reviewed clinical data or independent market estimates.